These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 9780612)

  • 1. Influence of delayed viral production on viral dynamics in HIV-1 infected patients.
    Mittler JE; Sulzer B; Neumann AU; Perelson AS
    Math Biosci; 1998 Sep; 152(2):143-63. PubMed ID: 9780612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Herz AV; Bonhoeffer S; Anderson RM; May RM; Nowak MA
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7247-51. PubMed ID: 8692977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials.
    Verotta D; Schaedeli F
    Math Biosci; 2002 Apr; 176(2):163-83. PubMed ID: 11916507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy.
    Dixit NM; Markowitz M; Ho DD; Perelson AS
    Antivir Ther; 2004 Apr; 9(2):237-46. PubMed ID: 15134186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the short-, middle- and long-term viral load responses for comparing estimated dynamic parameters.
    Huang Y
    Biom J; 2007 Jun; 49(3):429-40. PubMed ID: 17623347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Perelson AS; Neumann AU; Markowitz M; Leonard JM; Ho DD
    Science; 1996 Mar; 271(5255):1582-6. PubMed ID: 8599114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen.
    Notermans DW; Goudsmit J; Danner SA; de Wolf F; Perelson AS; Mittler J
    AIDS; 1998 Aug; 12(12):1483-90. PubMed ID: 9727569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics.
    Bortz DM; Nelson PW
    Bull Math Biol; 2004 Sep; 66(5):1009-26. PubMed ID: 15294416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies.
    Huang Y; Dagne G
    Stat Med; 2010 Oct; 29(23):2384-98. PubMed ID: 20603815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.
    Gadhamsetty S; Coorens T; de Boer RJ
    J Virol; 2016 Aug; 90(16):7066-7083. PubMed ID: 27226367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A model of HIV-1 pathogenesis that includes an intracellular delay.
    Nelson PW; Murray JD; Perelson AS
    Math Biosci; 2000 Feb; 163(2):201-15. PubMed ID: 10701304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABC of AIDS. Antiretroviral drugs.
    Weller IV; Williams IG
    BMJ; 2001 Jun; 322(7299):1410-2. PubMed ID: 11397751
    [No Abstract]   [Full Text] [Related]  

  • 14. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months.
    Di Mascio M; Dornadula G; Zhang H; Sullivan J; Xu Y; Kulkosky J; Pomerantz RJ; Perelson AS
    J Virol; 2003 Feb; 77(3):2271-5. PubMed ID: 12525664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the effect of highly active antiretroviral therapy on changes in human immunodeficiency virus type 1 RNA viral load using a marginal structural left-censored mean model.
    Cole SR; Hernán MA; Anastos K; Jamieson BD; Robins JM
    Am J Epidemiol; 2007 Jul; 166(2):219-27. PubMed ID: 17478436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of virus from lymphoid tissue affects human immunodeficiency virus type 1 and hepatitis C virus kinetics in the blood.
    Müller V; Marée AF; De Boer RJ
    J Virol; 2001 Mar; 75(6):2597-603. PubMed ID: 11222682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy with protease inhibitors in human immunodeficiency virus type 1- and human herpesvirus 8-coinfected patients.
    De Milito A; Catucci M; Venturi G; Romano L; Incandela L; Valensin PE; Zazzi M
    J Med Virol; 1999 Feb; 57(2):140-4. PubMed ID: 9892398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data.
    Pawelek KA; Liu S; Pahlevani F; Rong L
    Math Biosci; 2012 Jan; 235(1):98-109. PubMed ID: 22108296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
    Ioannidis JP; Havlir DV; Tebas P; Hirsch MS; Collier AC; Richman DD
    AIDS; 2000 Jul; 14(11):1481-8. PubMed ID: 10983634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mathematical analysis of delay differential equation models of HIV-1 infection.
    Nelson PW; Perelson AS
    Math Biosci; 2002; 179(1):73-94. PubMed ID: 12047922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.